TriCAR19.20.22 T Cells for Blood Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called TriCAR19.20.22 T cells to determine its safety and effectiveness for blood cancers like non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) that have recurred or resisted treatment. The treatment involves modifying a patient's immune cells in a lab to enhance their ability to attack cancer cells. This trial may suit individuals whose cancer has returned after treatment or did not improve with previous therapies. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you must be off immunosuppressive agents if you had an allogeneic stem cell transplant, and there are specific requirements for those with hepatitis B. It's best to discuss your current medications with the trial team to get a clear answer.
Is there any evidence suggesting that TriCAR19.20.22 T cells are likely to be safe for humans?
Research shows that TriCAR19.20.22 T cells might be safe and manageable for patients with certain blood cancers. These T cells are designed to find and attack specific proteins (CD19, CD20, and CD22) on cancer cells. Studies have shown that CAR T-cell therapies targeting these proteins have effectively treated blood cancers. So far, the treatments seem well-tolerated, with most patients not experiencing severe side effects. However, because this trial is in an early phase, researchers are still collecting detailed safety information. While there is some understanding of safety, more research is needed for a complete picture.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about TriCAR19.20.22 T cells because they offer a novel approach for treating blood cancers by targeting three specific proteins on cancer cells: CD19, CD20, and CD22. This multi-target strategy is distinct from standard therapies like chemotherapy and single-target CAR T-cell therapies, which often focus on just one protein. By simultaneously attacking multiple targets, TriCAR19.20.22 T cells have the potential to reduce cancer recurrence and improve treatment effectiveness. Additionally, these T cells are administered directly into the bloodstream, potentially leading to quicker and more direct action against the cancer cells.
What evidence suggests that TriCAR19.20.22 T cells might be an effective treatment for blood cancers?
Research shows that TriCAR19.20.22 T cells, which target specific proteins (CD19, CD20, and CD22) on cancer cells, could be promising for treating blood cancers. In this trial, participants will receive TriCAR19.20.22 T cells, with some receiving the treatment on day 0 and others on both days 0 and 7. Studies on similar CAR T-cell therapies have shown that more patients experience their cancer shrinking or stopping growth. This method involves altering a patient's immune cells to enhance their ability to fight cancer. Combining these targets might improve treatment for difficult-to-treat forms of non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Early results suggest that this triple-targeted therapy is safe and may work for some patients.13467
Who Is on the Research Team?
Sumithira Vasu, MD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for patients with certain blood cancers (like non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or didn't respond to previous treatments. Specific eligibility criteria are not provided but typically include factors like age, health status, cancer type and stage.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Apheresis
Patients undergo apheresis to collect T cells for modification
Lymphodepletion Chemotherapy
Patients receive lymphodepletion chemotherapy with cyclophosphamide and fludarabine
CAR T-cell Infusion
Patients receive TriCAR19.20.22 T cells infusion
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- TriCAR19.20.22 T Cells
Trial Overview
The trial is testing a new therapy called TriCAR19.20.22 T cells on patients whose blood cancer has relapsed or is refractory. It involves modifying the patient's own immune cells to target and attack their cancer cells.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Patients undergo apheresis between days -30 and -7 or days -9 and -7. Patients receive lymphodepletion chemotherapy with cyclophosphamide IV on day -6, fludarabine IV over 30 minutes on days -5 to -3 and TriCAR19.20.22 T cells IV over 5-30 minutes on days 0 and 7. Patients also undergo echocardiography or MUGA at baseline and blood sample collection and bone marrow biopsy and aspiration throughout the study. Additionally, patients undergo PET/CT as clinically indicated throughout the study.
Patients undergo apheresis between days -30 and -7 or days -9 and -7. Patients receive lymphodepletion chemotherapy with cyclophosphamide IV on day -6, fludarabine IV over 30 minutes on days -5 to -3. Patients then receive TriCAR19.20.22 T cells IV over 5-30 minutes on day 0. Patients also undergo echocardiography or MUGA at baseline and blood sample collection and bone marrow biopsy and aspiration throughout the study. Additionally, patients undergo positron emission tomography PET/CT as clinically indicated throughout the study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University Comprehensive Cancer Center
Lead Sponsor
Citations
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells ...
20.22 T cells may be safe, tolerable, and/or effective in treating patients with relapsed or refractory non-Hodgkin lymphoma, ALL and CLL.
2.
withpower.com
withpower.com/trial/phase-1-precursor-cell-lymphoblastic-leukemia-lymphoma-11-2025-12a84TriCAR19.20.22 T Cells for Blood Cancers
20.22 T cells may be safe, tolerable, and/or effective in treating patients ... 20.22 T cells on patients whose blood cancer has relapsed or is refractory.
TriCAR19.20.22 T cells / The Ohio State University ...
First-in-Human Phase I Study Results Presented: Trispecific CAR T-Cell Therapy (Blood Cancers Today) - P1 | N=36 | NCT05418088 | "A first-in-human phase I ...
Efficacy and safety of CD19 combined with CD22 or CD20 ...
The data from this study suggest that CD19 combined with CD22 CAR T-cell therapy had a higher partial response rate in the treatment of hematologic ...
Study Details | NCT07168486 | CD19.20.22 CAR T-cells ...
This is a phase 1a, open-label, single center study evaluating the safety and efficacy CAR19.20.22 in subjects with r/r B-cell malignancies. The ...
Efficacy and safety of CD19 combined with CD22 or CD20 ...
CD20 and CD22 CAR-T immunotherapies have achieved good results in hematological malignancies, including cases in which patients have previously ...
Efficacy and safety of CD22-specific and CD19/ ...
... safety of anti-CD22 or anti-CD19/CD22 CAR-T cell therapy in the treatment of hematological malignancies. 2) Outcomes included complete ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.